Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179660 · ClinicalTrials.gov registry record · Phase 2
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
A Phase 2 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00179660 is a Phase 2 study that has completed, run by Celgene Corporation. The registered enrollment target is 50 participants.
The verdict
NCT00179660, a Phase 2 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179660
The ClinicalTrials.gov registry entry for NCT00179660 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00179660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179660 about?
NCT00179660 is a clinical study titled "Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)". To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
What is the current status of trial NCT00179660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00179660?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00179660?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.